Alternatively, the up-regulation of follistatin may plausibly be a compensatory mechanism against the pathological increase of activin-A since a more recent study has also reported that follistatin inhibited cancer progression in a subset of pancreatic cancer cell lines that are known to highly express both activin β-subunits [64]. The gene discussed is FST; the disease is familial pancreatic carcinoma.